The Prospera SCS system for pain management relieved pain, improved sleep and reduced opioid use at 24 months, according to ...

Among 347,468 individuals who had lived with persistent pain for over 3 months, clinical symptoms of depression and anxiety ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced the successful ...

New research has identified cannabis-derived terpenes—compounds that give plants their distinctive aroma—as effective ...

Depression and anxiety affect approximately 40% of adults with chronic pain, according to a massive new systematic review and ...

U.S. researchers said Wednesday they have reproduced the pain-relieving effects of cannabis with a synthesized compound that ...

Terpenes from cannabis may relieve chronic pain without THC’s psychoactive effects. Researchers found that certain terpenes ...

VIP36, a new CB1 agonist, targets a cryptic pocket to provide analgesia for chronic pain while minimizing side effects and ...

Proceeds from today’s financing, when added to existing cash, fund operations through Q1 2026 The Company is planning to ...

MIRA Pharmaceuticals unveils Ketamir-2 topical for neuropathic pain, complementing its oral version. Clinical and preclinical ...

Dr. Richard Ibrahim, Principal Investigator for the IMPACT study ©️ Martin Leissl Cannabis-Based Therapy Shows Promise in ...